http://www.businesswire.com/news/home/20091016005046/en
LOS ANGELES--(Business Wire)--
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology
company, announced today that management will present a company overview at the
following two upcoming conferences:
Merriman Curhan Ford 6th Annual Investor Summit
Date: Tuesday, November 10, 2009
Time: 10:00 a.m. EST
Location: Hotel Sofitel New York
Lazard Capital Markets 6th Annual Healthcare Conference
Date: Tuesday, November 17, 2009
Time: 9:25 a.m. EST
Location: The St. Regis hotel in New York
A live webcast of each presentation will be available in the Investor Relations
section of the company`s website at www.abraxisbio.com. The webcasts will be
archived and accessible for at least 30 days.
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated
to the discovery, development and delivery of next-generation therapeutics and
core technologies that offer patients safer and more effective treatments for
cancer and other critical illnesses. The company's portfolio includes the
world's first and only protein-bound nanoparticle chemotherapeutic compound
(ABRAXANE®), which is based on the company's proprietary tumor targeting
technology known as the nab® platform. The first FDA approved product to use
this nab platform, ABRAXANE, was launched in 2005 for the treatment of
metastatic breast cancer and is now approved in 38 countries. The company
continues to expand the nab platform through a robust clinical program and deep
product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol
ABII. For more information about the company and its products, please visit
www.abraxisbio.com.
Investor & Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman
Director Investor Relations & Corporate Communications
310-883-1300
investorrelations@abraxisbio.com
or
PondelWilkinson Inc.
Rob Whetstone, 310-279-5963
Copyright Business Wire 2009
